Akiva Felt


Oppenheimer Reiterates Outperform on Zogenix, Inc. Following IND Update

In a research report issued yesterday, Oppenheimer analyst Akiva Felt reiterated an Outperform rating on shares of Zogenix, Inc. (NASDAQ:ZGNX) with a price target …

Oppenheimer Weighs in on Amarin Corporation plc (ADR) Following 2Q:15 Results

Oppenheimer analyst Akiva Felt weighed in with a few insights on Amarin Corporation plc (ADR)(NASDAQ:AMRN), after the pharmaceutical company released its second-quarter results last week. …

Oppenheimer Reiterates Upbeat View of Intercept Pharmaceuticals Inc Following Completed NDA Filing for Obethicholic Acid

Oppenheimer analyst Akiva Felt offered some commentary on Intercept Pharmaceuticals Inc (NASDAQ:ICPT) following the announcement that it has completed its NDA filing for obeticholic acid …

We Continue To See Upside Potential For Zogenix, Inc.: Oppenheimer

Oppenheimer’s healthcare analyst Akiva Felt reiterated an Outperform rating on Zogenix, Inc. (NASDAQ:ZGNX) with a $2.

Oppenheimer Boosts Price Target for Dyax Corp. as DX-2930 Data Results ‘Smashes Expectations’

Dyax Corp. (NASDAQ:DYAX) shares are up 47% today after the company announced positive data from the Phase 1b clinical study of its investigational product, DX-2930, which is being developed …

Oppenheimer Maintains Cautious Stance On Amarin Following 4Q14 Results

Oppenheimer analyst Akiva Felt came out with his views on Amarin Corporation plc (ADR) (NASDAQ:AMRN), after the company reported its fourth-quarter financial results. The company reported quarterly …

Intercept: The FDA ‘Breakthrough’ Status Could Be A Major Momentum Changer For The Stock, Says Oppenheimer

In a research report sent to investors, Oppenheimer analyst Akiva Felt reiterated an Outperform rating on Intercept Pharmaceuticals (NASDAQ:ICPT) with a price target …

Oppenheimer Raises Neuroderm Price Target Following ND0612 Phase 2 Update

Oppenheimer analyst Akiva Felt maintained an Outperform rating on Neuroderm (NASDAQ:NDRM) and slightly raised his price target to $19 (from $18), which implies …

Oppenheimer Comments On Cubist Pharmaceuticals As Merck Is Nearing An $8B Takeover

Oppenheimer analyst Akiva Felt joined the crowd today, reiterating an Outperform rating on Cubist Pharmaceuticals (NASDAQ:CBST) while also, surprisingly, keeping his price target at $83, as multiple news outlets reported …

Oppenheimer Reiterates Outperform On Mallinckrodt Following Investors Meeting

In a research report issued today, Oppenheimer analyst Akiva Felt reiterated an Outperform rating on Mallinckrodt (NYSE:MNK) with a $111 price target, which …